Factors Associated with Neutralizing Antibody Responses following 2-Dose and 3rd Booster Monovalent COVID-19 Vaccination in Japanese People Living with HIV
Authors:
- Isaac NgareINIsaac Ngare
- Toong Seng TanTTToong Seng Tan
- Mako ToyodaMTMako Toyoda
- Takeo KuwataTKTakeo Kuwata
- Soichiro TakahamaSTSoichiro Takahama
- Eriko NakashimaENEriko Nakashima
- Naoya YamasakiNYNaoya Yamasaki
- Chihiro MotozonoCMChihiro Motozono
- Teruhisa FujiiTFTeruhisa Fujii
- Rumi MinamiRMRumi Minami
- Godfrey BarabonaGBGodfrey Barabona
- Takamasa UenoTUTakamasa Ueno
Open Access
Abstract
People living with HIV (PLWH) could be at risk of blunted immune responses to COVID-19 vaccination. We investigated factors associated with neutralizing antibody (NAb) responses against SARS-CoV-2 and variants of concern (VOCs), following two-dose and third booster monovalent COVID-19 mRNA vaccination in Japanese PLWH. NAb titers were assessed in polyclonal IgG fractions by lentiviral-based pseudovirus assays. Overall, NAb titers against Wuhan, following two-dose vaccination, were assessed in 82 PLWH on treatment, whereby 17/82 (20.73%) were classified as low-NAb participants. Within the low-NAb participants, the third booster vaccination enhanced NAb titers against Wuhan and VOCs, albeit to a significantly lower magnitude than the rest. In the multivariate analysis, NAb titers against Wuhan after two-dose vaccination correlated with age and days since vaccination, but not with CD4+ count, CD4+/CD8+ ratio, and plasma high-sensitivity C-Reactive protein (hsCRP). Interestingly, an extended analysis within age subgroups revealed NAb titers to correlate positively with the CD4+ count and negatively with plasma hsCRP in younger, but not older, participants. In conclusion, a third booster vaccination substantially enhances NAb titers, but the benefit may be suboptimal in subpopulations of PLWH exhibiting low titers at baseline. Considering clinical and immune parameters could provide a nuanced understanding of factors associated with vaccine responses in PLWH.Keywords
Funding Information
- AMED Research Program on HIV/AIDS (23fk0410050h0302, 23fk0410054h0002, 20fk0108539h0001, 20fk0108451s0101, 22H03119, 22KK0148)
- AMED Research Program on Emerging and Re-Emerging Infectious Diseases (23fk0410050h0302, 23fk0410054h0002, 20fk0108539h0001, 20fk0108451s0101, 22H03119, 22KK0148)
- JSPS KAKENHI (23fk0410050h0302, 23fk0410054h0002, 20fk0108539h0001, 20fk0108451s0101, 22H03119, 22KK0148)
- Grant-in-Aid for Scientific Research (23fk0410050h0302, 23fk0410054h0002, 20fk0108539h0001, 20fk0108451s0101, 22H03119, 22KK0148)
- Japanese Government (Monbukagakusho: MEXT) Scholarship (23fk0410050h0302, 23fk0410054h0002, 20fk0108539h0001, 20fk0108451s0101, 22H03119, 22KK0148)
This publication has 41 references indexed in Scilit:
- Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profilesiScience, 2022
- COVID-19 Outcomes and Risk Factors Among People Living with HIVCurrent HIV/AIDS Reports, 2022
- Mechanisms underpinning poor antibody responses to vaccines in ageingImmunology Letters, 2022
- Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in JapanClinical Microbiology and Infection, 2021
- Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273JAMA, 2021
- Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19Cell Reports, 2021
- Determinants of suboptimal CD4+ T cell recovery after antiretroviral therapy initiation in a prospective cohort of acute HIV‐1 infectionJournal of the International AIDS Society, 2020
- HIV and agingInternational Journal of Infectious Diseases, 2016
- Measuring HIV Neutralization in a Luciferase Reporter Gene Assay2009
- C-Reactive Protein Is a Marker for Human Immunodeficiency Virus Disease ProgressionArchives of internal medicine (1960), 2006